{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for acetohydroxamic root_Display\ Name in Display Name (approximate match)
Status:
Possibly Marketed Outside US
Source:
21 CFR 333A
(2010)
Source URL:
First approved in 1994
Source:
M003
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT01896596: Phase 4 Interventional Completed Meningococcal Disease
(2013)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
G1 SPECIFIED SUBSTANCE
Status:
Investigational
Source:
NCT02144051: Phase 1 Interventional Completed Advanced Solid Tumours With Androgen Receptor Pathway as a Potential Factor
(2014)
Source URL:
Class:
CONCEPT
Status:
Other
Class:
CONCEPT
Status:
Other
Class:
CONCEPT
Status:
Other
Class:
CONCEPT
Status:
Other
Class:
CONCEPT
Status:
Other
Class:
CONCEPT